drugset / Trial / NCT05742126

A Study of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Dosed of HSK36273 in Healthy Volunteers

NCT05742126

Phase 1 Completed 54 enrolled Haisco Pharmaceutical Group Co., Ltd.
RandomizedParallel-groupDouble-blindOther

Summary

This is a single-center, Phase 1, placebo and positive-controlled, randomized, partial-blind, integrated, sequential ascending dose / multiple ascending dose study.The safety, tolerability, pharmacokinetics and pharmacodynamics of multiple continuous IV infusion ascending doses of HSK36273 in healthy volunteers will be evaluated.

Timeline

Start
2022-04-11
Primary completion
2022-09-12
Completion
2022-09-15

Drugs

EvaluationDrugModalityDoseRoute
Subject HSK36273 Unknown Intravenous
Comparator Heparin sodium injection Unknown

Indications

No indication recorded.